ArticleExperimental hematology & oncology2023

Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting.

Jiaxiong Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.